Drugs / Insulin, Asp(B28)-
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT02101229 | May 2014 → Feb 2015 | type 1 diabetes mellitus | Centre d'Etudes et de Recherche pour l'Intensification du Traitement du Diabète | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT02419859 | Feb → Nov 2015 | type 2 diabetes mellitus | CeQur Corporation | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT00797823 Background | Nov 2008 → Sep 2009 | type 1 diabetes mellitus | Legacy Health System | Completed | No outcome recorded |
| — | NCT01643382 Comparator | Aug 2012 → Aug 2014 | diabetes mellitus, end stage renal failure | University of California, San Francisco | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Insulin, Asp(B28)- | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02419859 ↗ |
| Modality | Protein / enzyme biologic | “a fast-acting analog of human insulin” NCT02419859 ↗ |
| Route | Subcutaneous | “These catheters will allow for SC delivery of insulin and glucagon (or insulin plus a glucagon placebo).” NCT00797823 ↗ |